Market Overview:

The Inhaled Nitric Oxide Market is experiencing steady expansion, driven by Growing Prevalence of Respiratory Diseases in Newborns, Rising Geriatric Population and Increasing Investments in Advanced Healthcare Infrastructure. According to IMARC Group's latest research publication, "Inhaled Nitric Oxide Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025–2033", offers a comprehensive analysis of the industry, which comprises insights on the global inhaled nitric oxide market share. The global market size was valued at USD 1,002.83 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 1,732.93 Million by 2033, exhibiting a CAGR of 5.64% from 2025-2033.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers  and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

Download a sample PDF of this report: https://www.imarcgroup.com/inhaled-nitric-oxide-market/requestsample

Our Report Includes:

• Market Dynamics
• Market Trends and Outlook
• Competitive Analysis
• Industry Segmentation
• Strategic Recommendations

Growth Factors in the Inhaled Nitric Oxide Industry:

• Growing Prevalence of Respiratory Diseases in Newborns

The increasing prevalence of respiratory and other subsequent diseases in newborns is propelling the market growth. Many premature babies suffer from hypoxic respiratory failure and persistent pulmonary hypertension, conditions where inhaled nitric oxide helps to improve oxygen levels and reduce the need for invasive procedures like extracorporeal membrane oxygenation (ECMO). According to the NIH, lower respiratory infections in children under five accounted for 37.8 Million cases, 501,910 deaths, and 44.8 Million disability-adjusted life years worldwide. As preterm births rise globally, hospitals and neonatal care units rely more on this therapy to reduce complications. Regulatory approvals and clinical guidelines further support its widespread use in NICUs. With high healthcare investments and enhanced neonatal care, the demand for inhaled nitric oxide is rising.

• Rising Geriatric Population

The growing geriatric population is positively influencing the market. Older adults are more susceptible to hypertension, atherosclerosis, peripheral artery disease, heart failure, and thrombosis, all of which require inhaled nitric oxide for vasodilation. As per a 2024 MDPI report, heart failure prevalence rose with age, annually affecting about 1% of individuals under 55 and exceeding 10% in those over 70. The elderly population is also relatively more prone to conditions like COPD, pulmonary hypertension, and ARDS, creating the need for effective oxygen therapy. Inhaled nitric oxide helps to improve oxygen flow and reduce lung pressure, making it a crucial treatment for elderly patients. As life expectancy rises, healthcare systems focus on advanced respiratory treatments, leading to higher adoption.

• Increasing Investments in Advanced Healthcare Infrastructure

The rising investments in advanced healthcare infrastructure are fueling the inhaled nitric oxide market growth. According to the information provided on the official website of the International Trade Administration (ITA), in 2024, the Indian Government launched five new All India Institute of Medical Sciences (AIIMS) centers and introduced a total of 202 healthcare infrastructure initiatives throughout the country to promote progress in healthcare technologies. Well-equipped hospitals, specialized neonatal care units, and modern intensive care facilities widely employ inhaled nitric oxide for treating conditions like hypoxic respiratory failure, pulmonary hypertension, and ARDS. The availability of advanced medical equipment improves the efficiency of inhaled nitric oxide therapy, making it more effective for both newborns and adults with respiratory disorders.

Key Trends in the Inhaled Nitric Oxide Market

• Development of Portable Delivery Systems

The market is witnessing significant innovation in portable inhaled nitric oxide delivery systems that eliminate bulky gas cylinders, improving hospital efficiency and patient care. In February 2024, Third Pole Therapeutics reported the successful conclusion of a preliminary feasibility study for eNOfit, a portable delivery system for inhaled nitric oxide aimed at treating pulmonary hypertension linked to interstitial lung disease. The two-pound appliance enabled use at home and while on the go. Regulatory approvals for portable and home-use inhaled nitric oxide devices are expanding accessibility beyond hospital settings.

• Expansion Beyond Neonatal Applications

While neonatal respiratory treatment held 86.1% of the market share in 2024, there is growing adoption in adult applications including COPD, acute respiratory distress syndrome, and pulmonary hypertension. Research into inhaled nitric oxide's role in treating post-operative care and critical respiratory conditions is driving demand in adult intensive care units. The expansion into broader therapeutic areas is creating new market opportunities and revenue streams for manufacturers and healthcare providers.

• Integration of Digital Health and Precision Dosing

Healthcare systems are increasingly integrating digital health technologies with inhaled nitric oxide therapy for real-time monitoring and precision dosing. Advanced delivery systems now feature AI-based monitoring capabilities that optimize treatment protocols based on patient response. These smart systems enable healthcare providers to adjust dosing parameters dynamically, improving treatment outcomes while reducing waste. The focus on precision medicine and personalized treatment approaches is transforming inhaled nitric oxide therapy from standardized protocols to patient-specific interventions.

Leading Companies Operating in the Global Inhaled Nitric Oxide Industry:

• Air Liquide S.A
• Bellerophon Therapeutics
• Beyond Air Inc.
• Linde plc
• Mallinckrodt plc
• Merck KGaA
• Novoteris LLC
• Nu-Med Plus
• VERO Biotech LLC

Inhaled Nitric Oxide Market Report Segmentation:

Breakup by Application:

• Neonatal Respiratory Treatment
• Chronic Obstructive Pulmonary Disease (COPD)
• Acute Respiratory Distress Syndrome (ARDS)
• Others

Neonatal respiratory treatment held 86.1% of the market share in 2024 as it is the primary therapy for newborns with hypoxic respiratory failure and persistent pulmonary hypertension.

Breakup by Region:

• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America, accounting for 77.7%, enjoys the leading position in the market due to strong healthcare infrastructure, high prevalence of respiratory diseases, advanced research, and favorable regulatory policies.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1–201971–6302